16:38 , Jan 12, 2018 |  BC Week In Review  |  Company News

Moderna advances pipeline with Phase II of AZD-8601

Moderna Therapeutics Inc. (Cambridge, Mass.) said AZD-8601 will be its first program to advance into Phase II testing. This quarter, the company plans to begin a Phase IIa trial of the candidate, which is partnered...
07:00 , May 11, 2015 |  BC Week In Review  |  Company News

City of Hope, Fortress Biotech deal

City of Hope granted Fortress’ newly formed DiaVax Biosciences subsidiary exclusive, worldwide rights to develop and commercialize Triplex and PepVax -- two T cell immunotherapeutic peptide vaccines. Fortress also has an option to license exclusive,...